Ujvira 100mg Dry Vial Of 1 Powder For Injection
1 Powder For Injection(s) in Dry VialMRP ₹37044.00
₹19633.32
47% OFF
Made by
ZYDUS LIFESCIENCES LIMITED
Dosage
POWDER FOR INJECTION
Expiry
Product Summary
| Salt Content | Trastuzumab Emtansine(100.0 Mg) |
| Uses | Breast cancers |
| Therapy | Anti-neoplastic |
| Side effects | Thrombocytopenia, anaemia, peripheral neuropathy, headache, and epistaxis (nosebleed) |
Assurance
available
Regulated
Medical Description
Ujvira powder for injection contains trastuzumab emtansine, a prescription medication for treating HER2-positive breast cancer. This drug combines trastuzumab, an antibody targeting HER2 receptors, with emtansine, a chemotherapy agent that destroys cancer cells. Ujvira powder for injection is indicated for both early and advanced stages of breast cancer, particularly in cases where the disease recurs within six months following chemotherapy.
Ujvira powder for injection may cause side effects like nausea, vomiting, diarrhoea, and hair loss. Tell your doctor right away if you experience any allergic reactions or unusual bleeding. Ujvira powder for injection typically does not harm your kidneys. In rare cases, you might react to the infusion. Always talk to your healthcare provider for personalized medical advice.
Uses
Contraindications
Side effects
- Thrombocytopenia
- Anaemia
- Peripheral neuropathy
- Headache
- Epistaxis (nosebleed)
- Cough
- Dyspnoea
- Stomatitis
- Diarrhoea
- Vomiting
- Nausea
- Constipation
- Dry mouth
- Abdominal pain
- Rash
- Pruritus
- Alopecia
- Nail disorder
- Musculoskeletal pain
- Arthralgia
- Myalgia
- Fatigue
- Pyrexia
- Asthenia
Precautions and Warnings
Pregnancy
Breast Feeding
Driving
Alcohol
Other General Warnings
- You have kidney disease, have undergone a kidney transplant, or have any history of liver disease.
- You are taking anticoagulants or antiplatelet medicines, such as warfarin or heparin.
- You have a history of thrombocytopenia (low platelet count) or are experiencing any signs of unusual bleeding or bruising.
- You have or have had heart conditions such as congestive heart failure, arrhythmias, or a history of myocardial infarction.
- You have a low left ventricular ejection fraction (LVEF) or heart-related symptoms, such as shortness of breath or chest pain.
- You are experiencing symptoms of peripheral neuropathy, such as numbness, tingling, or weakness in your extremities.
- You have experienced any infusion-related reactions or severe allergic reactions to trastuzumab or similar medicines in the past.
- You have a history of lung disease, interstitial lung disease, or pneumonitis.
- You are experiencing symptoms like persistent cough, fatigue, or difficulty breathing.
- You are undergoing or planning to undergo concurrent radiation therapy.
- You are pregnant, planning to become pregnant, or breastfeeding.
- You have any signs of liver dysfunction, such as yellowing of the skin or eyes, dark urine, or unusual fatigue.
- You are on any other medications or supplements, including herbal products, that could interact with trastuzumab emtansine.
- You have a history of hypersensitivity or anaphylactic reactions to medications.
- You experience any injection-site reactions, including pain, redness, or swelling during or after administration.
Directions for Use
Storage and disposal
Dosage
Overdose
Missed a Dose
Mode of Action
How Does It Work?
Interactions
Interactions with other medicines
Articles
View AllChronic Condition Articles
View AllDid you find this helpful?
Explore More at Pharmeasy
Manufacturer Details
Brand:UJVIRA
Manufacturer Name:ZYDUS LIFESCIENCES LIMITED
Address:Cadila Healthcare Ltd - Kuadaim Industrial Estate,Plot no. 203-213, Kundaim, Goa-403115,india.
Country of Origin:India
Vendor Details
Fulfillment Information: Ujvira 100 MG Powder For Injection (1) will be delivered by a licensed retail pharmacy nearest to your location. Order acceptance and fulfillment are dependent upon the verification of your doctor's valid prescription (where applicable) and the current stock of this medicine.
References:
- Herceptin 150mg Powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc) [Internet]. Medicines.org.uk. 2025 [cited 6 January 2025]
- Herceptin 150mg Powder for concentrate for solution for infusion - Patient Information Leaflet (PIL) - (emc) [Internet]. Medicines.org.uk. 2025 [cited 6 January 2025]
- Kadcyla 100 mg Powder for Concentrate for Solution for Infusion - Summary of Product Characteristics (SmPC) - (emc) [Internet]. Medicines.org.uk. 2025 [cited 6 January 2025]
- https://www.medicines.org.uk/emc/files/pil.9537.pdf
In Case of Any Issues Contact Us
Email Id:care@pharmeasy.in
Phone Number:7666100300
Address:D-37/1, Opp. Sandoz, TTC Industrial Area, MIDC Industrial Area, Turbhe, Navi Mumbai, Maharashtra 400703
Disclaimer
The information provided herein is supplied to the best of our abilities to make it accurate and reliable as it is published after a review by a team of professionals. This information is solely intended to provide a general overview on the product and must be used for informational purposes only. You should not use the information provided herein to diagnose, prevent, or cure a health problem. Nothing contained on this page is intended to create a doctor-patient relationship, replace or be a substitute for a registered medical practitioner's medical treatment/advice or consultation. The absence of any information or warning to any medicine shall not be considered and assumed as an implied assurance. We highly recommend that you consult your registered medical practitioner for all queries or doubts related to your medical condition. You hereby agree that you shall not make any health or medical-related decision based in whole or in part on anything contained in the Site. Please click here for detailed T&C.





















